DECLARATION, POWER OF ATTORNEY, AND PETITION

I, a below named inventor, depose and say that: (1) my residence, citizenship, and mailing address are indicated below; (2) I have reviewed and understand the contents of my patent application, including the claims, as amended by any amendment specifically referred to herein, which is identified as U.S. Patent Application Serial No. 10/011,921, filed December 6, 2001; (3) I believe that the other below named inventors and I are the original, first, and joint inventors of the invention or discovery in

HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES

described and claimed therein and for which a patent is sought; and (4) this application in part discloses and claims subject matter disclosed in my earlier filed patent application, Serial No. 60/254,218 filed December 8, 2000, and claims priority to that application; (5) I hereby acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to the patentability as defined in Title 37, Code of Federal Regulations, §1.56.*

I hereby appoint Gregory D. Allen (Reg. No. 35,048), Alan Ball (Reg. No. 42,286), Scott A. Bardell (Reg. No. 39,594), Carolyn A. Bates (Reg. No. 27,853), Bruce E. Black (Reg. No. 41,622), Colene E. H. Blank (Reg. No. 41,056), Jennie G. Boeder (Reg. No. 28,952), William J. Boud (Reg. No. 32,400), Stephen W. Buckingham (Reg. No. 30,035), John A. Burtis (Reg. No. 39,924), Melissa E. Buss (Reg. No. 47,465), James D. Christoff (Reg. No. 31,492), Philip Y. Dahl (Reg. No. 36,115), Dean A. Ersfeld (Reg. No. 46,689), Lisa M. Fagan (Reg. No. 40,601), Carolyn A. Fischer (Reg. No. 39,091), Yen T. Florczak (Reg. No. 45,163), Melanie G. Gover (Reg. No. 41,793), Christopher D. Gram, (Reg. No. 43,643), Gary L. Griswold (Reg. No. 25,396), Doreen S. L. Gwin (Reg. No. 35,580), Karl G. Hanson (Reg. No. 32,900), Dean M. Harts (Reg. No. 47,634), Néstor F. Ho (Reg. No. 39,460), Stephen C. Jensen (Reg. No. 35,207), George W. Jonas (Reg. No. 46,811), Robert H. Jordan (Reg. No. 31,973), Harold C. Knecht III (Reg. No. 35,576), Kent S. Kokko (Reg. No. 33,931), Nancy M. Lambert (Reg. No. 44,856); James V. Lilly (Reg. No. 27,817), Douglas B. Little (Reg. No. 28,439), Jean Lown (Reg. No. 48,428), Eloise J. Maki (Reg. No. 33,418), Michelle M. Michel (Reg. No. 33,968), William D. Miller (Reg. No. 37,988), Peter L. Olson (Reg. No. 35,308), Daniel R. Pastirik (Reg. No. 33,025), David B. Patchett (Reg. No. 39,326), Robert J. Pechman (Reg. No. 45,002), Carolyn V. Peters (Reg. No. 33,271), Scott R. Pribnow (Reg. No. 43,869), Kevin H. Rhodes (Reg. No. 42,102), Ted K. Ringsred (Reg. No. 35,658), Steven E. Skolnick (Reg. No. 33,789), Robert W. Sprague (Reg. No. 30,497), Brian E. Szymanski (Reg. No. 39,523), James J. Trussell (Reg. No. 37,251), Lucy C. Weiss (Reg. No. 32,834), and Bradford B. Wright (Reg. No. 34,459) my attorneys and/or agents with full powers (including the powers of appointment, substitution, and revocation) to prosecute this application and any division, continuation, continuation-in-part, reexamination, or reissue thereof, and to transact all business in the Patent and Trademark Office connected therewith; the mailing address and the telephone number of the above-mentioned attorneys and/or agents are

Attention: Dean A. Ersfeld Office of Intellectual Property Counsel 3M Innovative Properties Company P.O. Box 33427 St. Paul, Minnesota 55133-3427 Telephone No. 651-733-7830

The undersigned petitioner declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Wherefore, I pray for grant of Letters Patent for the invention or discovery described and claimed in the aforementioned specification and we hereby subscribe our names to the foregoing specification and claims, declaration, power of attorney, and this petition, on the day set forth below.

Leslie J. Charles

Hudson, Wisconsin U.S.A. Residence:

Citizenship: United States of America P.O. Box 33427

Post Office

St. Paul, Minnesota 55133-3427 Address:

3
e
•
03
te
•
٠.
03
ate
03
Date
٠.
) <u>3</u>
Date
•
003
Date

§1.56 Duty to disclose information material to patentability.

- (a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:
 - (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
 - (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.
 - (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
 - (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
 - (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability. A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.
 - (c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:
 - (1) Each inventor named in the application;
 - (2) Each attorney or agent who prepares or prosecutes the application; and
 - (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.
 - Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.

First Named Inventor: CHARLES, LESLIE Case No.: 57072US002 Application No.: 10/011921 Title: Heteroaryl Ether Substituted Imidazoquinolines Enclosures: Submissi n of Substitute Declarati n, Pow r of Attorney and Petition; Executed Declaration, P wer f Attorney and Petition. Amount charged to Deposit Account: \$0 Attorney (initials): DAE/raw Date: 17 February 2003	· ·		
Application No.: 10/011921 Title: HETEROARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES Enclosures: Submissi n of Substitute Declarati n, Pow r of Attorney and Petition; Executed Declaration, P wer f Attorney and Petition. Amount charged to Deposit Account: \$0		First Named Inventor: CHARLES, LESLIE	
Application No.: 10/011921 Title: HETEROARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES Enclosures: Submissi n of Substitute Declarati n, Pow r of Attorney and Petition; Executed Declaration, P wer f Attorney and Petition. Amount charged to Deposit Account: \$0		Case No.: 57072US002	
Title: HETEROARYL ETHER SUBSTITUTED IMIDAZOGU Enclosures: Submissi n of Substitute Declarati n, Pow r of Attorney and Petition; Executed Declaration, P wer f Attorney and Petition. Amount charged to Deposit Account: \$0		No. 40/011921	
Submissi n of Substitute Declaration, P wer f Attorney and Petition; Executed Declaration, P Attorney and Petition. Attorney and Petition. Amount charged to Deposit Account: \$0	Periodici di Sensi di Periodici di Periodici di Sensi di Periodici di Periodici di Periodici di Periodici di P Periodici di Periodici di Periodi	Title: HETEROARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES	
Submissi n of Substitute Declaration, P wer f Attorney and Petition; Executed Declaration, P Attorney and Petition. Attorney and Petition. Amount charged to Deposit Account: \$0	en kan di kan si seperangan kan di kan	Enclosures:	
Amount charged to Deposit Account: 50		Attorney and Petition.	ract
AND THE REAL PROPERTY OF THE P		Amount charged to Deposit Account: \$0	
Date: 17 February 2002		DAEIrow	
		Date: 17 February 2003	
		<u> </u>	·

	1.	and the state of t	